Brazil Class I and II Devices: The 30-Day Notification Pathway

1. Key takeaways

Class I (low-risk) and Class II (medium-risk) devices in Brazil follow the notification (notificação) pathway, and the statutory processing limit set by ANVISA is 30 days. GRZAN’s assessment is unambiguous: this 30-day figure is a routine administrative processing window at the formal level, and it does not mean the technical documentation can be skipped. What the notification pathway saves is review depth, not documentation obligations. The notification holder must still maintain a technical dossier under Article 56 of RDC 751/2022, and before publication in the DOU the device may not be industrialized, imported, displayed for sale, or delivered for consumption. The dividing line between the two premarket routes is drawn by Article 6 and Article 7 of RDC 751/2022: Classes I and II go through notification, Classes III and IV go through registration (registro), and the two routes differ in both review depth and documentation requirements. Reading 30 days directly as a fast, inspection-free lane is the single most frequent misjudgment GRZAN has encountered in Brazil projects.

2. Legal basis

• Requirements for the classification, notification and registration of medical devices and for labeling and instructions for use — RDC nº 751/2022, resolution of September 15, 2022: Article 10(6), Article 10(9), Article 10(10), Article 56, and Article 60(1)
• Requirements for the classification, notification and registration of medical devices and for labeling and instructions for use — RDC nº 751/2022, resolution of September 15, 2022: Article 5, Article 6, and Article 4(VIII)
• Transfer of ownership and cancellation of product registrations — RDC nº 903/2024, published in the DOU on September 9, 2024: Article 28 (article numbers and key points compiled from multiple consistent sources; verify against the DOU or anvisalegis before final publication)

3. Expert insights

Why did the legislator define notification as routine processing? GRZAN’s reading is that low-risk and medium-risk devices do not justify consuming scarce review resources, and that enforcement capacity should be concentrated on the technical review of Class III (high-risk) and Class IV (maximum-risk) devices. The real consequence of this design is that the burden of proof shifts downstream: the fact that ANVISA does not verify each item at submission does not mean the company is relieved of compliance obligations. It means the moment of verification has been moved to post-market inspection and technovigilance. A notification holder that cannot produce a technical dossier on demand is exposed precisely where the routine pathway is least protective.

Companies commonly fall into 2 traps. The first is treating notification as a mere filing exercise: a product list is submitted, and when ANVISA conducts a spot check or an adverse event occurs, no technical dossier can be produced, which lands the company directly on the penalty list under Lei 6.437/1977. The second is ignoring the language tiering: the application form, the instructions for use (IFU), and the label mock-ups must be in Portuguese, while the remaining documents may be submitted in Portuguese, Spanish, or English. Submitting an English-language IFU is the most common formal defect GRZAN sees at the intake stage.

One further point is often misunderstood: 30 days describes ANVISA’s processing time, not a countdown promise made to the company. When documentation is incomplete and a deficiency notice is triggered, the way the clock is counted changes accordingly. GRZAN’s project experience in Brazil is that planning production schedules around 30 days as the total cycle usually underestimates the real time needed (overall timelines are a practical estimate; defer to ANVISA published figures and case-specific responses).

On positioning, GRZAN’s judgment is this: the investment focus on the notification pathway should not be on getting through submission, but on being able to withstand later scrutiny. The file you build is not for the application form; it is for the day an inspector or a complaint arrives.

4. Practical recommendations

First, build the dossier to Class III/IV standards. Organize the internal technical dossier into 4 categories — risk management, performance verification, labeling, and instructions for use — so that even if nothing is checked at submission, the complete set can be produced in one pass during a spot check.

Second, do the Portuguese work first. The GRZAN regulatory team recommends finalizing the Portuguese versions of the IFU and the label mock-ups before submission, so that no change procedure is needed after publication in the DOU.

Third, price the non-transferability into the licensing structure. Under Article 28 of RDC 903/2024, notification (notificação) products may not undergo a transfer of ownership; the only option is to file again. This directly affects the choice between having a distributor hold the notification and setting up a subsidiary to hold it. GRZAN’s judgment: where channel stability is low, the long-term cost of holding the notification through your own entity is usually lower than repeated re-filing.

Fourth, zero activity before DOU publication: no industrialization, no import, no display for sale, and no delivery for consumption may occur.

Fifth, write the non-transferability into commercial contracts. Any change of distributor or corporate restructuring will trigger re-filing. GRZAN recommends agreeing in the distribution contract in advance on who bears the re-filing responsibility and costs on exit, to avoid disputes after the fact.

5. Verification checklist

• □ The risk class has been confirmed as Class I or Class II under Article 5 of RDC 751/2022, and the pathway is notification
• □ The application form, IFU, and label mock-ups have been finalized in Portuguese
• □ The technical dossier has been built under Article 56 and can be retrieved on demand
• □ The holder structure (detentor de notificação) has been decided, with the knowledge that notifications are non-transferable
• □ The distribution contract already allocates re-filing responsibility and costs
• □ No import, display for sale, or delivery for use has occurred before DOU publication

Regulatory information verified as of October 29, 2026

GRZAN Regulatory Affairs Team

GRZAN supports manufacturers entering the Brazilian market with ANVISA registration pathway selection and classification strategy, covering the notification and registration routes under RDC 751/2022, dossier structuring that survives post-market scrutiny, and Portuguese-language documentation planning. Whether you are launching a single Class II device or building a full Brazil portfolio, the GRZAN regulatory team can help you sequence filings, licenses, and commercial structures correctly from day one. For tailored guidance, contact us at info@grzanglobal.com.